Tajikistan Batch Release and Post-Market Quality Control: GMP Exemption Rules

1. Key takeaways

Tajikistan sets up a post-market quality control mechanism of batch-by-batch (series-by-series) conformity assessment plus quality certificates for registered products. Article 13(1) provides that conformity assessment is carried out to determine whether a specific series (batch) imported into the country or produced within the territory meets the requirements of the quality control normative documents, and after a successful assessment a quality certificate is issued by the State Supervisory Authority for Pharmaceutical Activity and its subordinate bodies. GRZAN highlights two key design features. First, Article 13(4) is the only expressly stated exemption route — products holding a good manufacturing practice (GMP) conformity certificate, as well as their manufacturers and importers, are exempt from the batch-by-batch conformity assessment procedure. Second, Article 13(2) locks the power to set service rates and procedures as jointly exercised by the Ministry of Health and the antitrust policy authority, so rates are not decided by a single department.

2. Legal basis

3. Expert insights

Insight 1: the exemption subjects under Article 13(4) cover both ends, manufacturers and importers, not manufacturers alone. The provision refers to manufacturers and importers holding a good manufacturing practice conformity certificate, which means that the importer must also hold a GMP conformity certificate to enjoy the exemption. GRZAN points out that this is a relatively uncommon design in the Central Asia market, and when planning importer qualifications companies must include the importer-side GMP certificate in their budgets and schedules.

Insight 2: the exemption applies to the batch-by-batch conformity assessment procedure, not to the release from quality obligations. Article 13(4) exempts the series assessment procedure under paragraph 3; it does not exempt the quality, effectiveness and safety requirements under Article 15(1), nor the post-market testing and monitoring under Article 12(4)(3) and (4). Companies must distinguish procedural exemption from substantive obligation.

Insight 3: the dual-department rate mechanism of Article 13(2) provides price predictability. The service procedure and payment rates for quality conformity assessment are developed jointly by the Ministry of Health and the antitrust policy authority, an arrangement that institutionally limits the pricing discretion of a single department. When estimating costs, companies should rely on the current text approved by both departments; the specific amounts should follow the payment documents issued by the competent authority, which is a practical estimate.

Insight 4: Article 13(5) assigns the power to classify device risk to the Ministry of Health in agreement with the supervisory authority. This classification directly affects the frequency of testing and the intensity of supervision, and it is a matter companies should confirm at the registration stage rather than after entering the market.

Insight 5: Article 12(4) lists five methods of state supervision, of which items 3 and 4 point directly to post-market quality. Item 3 is quality testing and item 4 is research and monitoring of effectiveness and safety. Together with pharmacovigilance under Article 20 and withdrawal under Article 21, they form the triple post-market supervision network.

4. Practical recommendations

1. Plan GMP certificates on both the manufacturer and importer sides at the same time. Under Article 13(4), the exemption subjects include importers, so the importer-side GMP conformity certificate must be included in entity qualification planning.
2. Estimate costs using the current rate text approved by both departments. Under Article 13(2), rates are set jointly by the Ministry of Health and the antitrust policy authority; obtain the current text for cost estimation, with amounts following the payment documents.
3. Track the series assessment procedure determined by the Ministry of Health. Under Article 13(3), the implementation arrangements are determined by the Ministry of Health, and production scheduling must follow the latest published version.
4. Confirm the risk classification result at the registration stage. Under Article 13(5), treat product risk classification as a confirmation item at registration and use it to anticipate testing intensity.
5. Distinguish procedural exemption from substantive obligation. Under Article 13(4) and Article 15(1), even with a procedural exemption, products must continuously meet quality, effectiveness and safety requirements.

5. Verification checklist

• □ Confirmed that the assessment object under Article 13(1) is a specific series (batch) and that a quality certificate is issued
• □ Confirmed that the exemption subjects under Article 13(4) include both manufacturers and importers
• □ Obtained the current procedure and rate text approved jointly by the two departments under Article 13(2)
• □ Obtained the latest version of the series assessment procedure determined by the Ministry of Health under Article 13(3)
• □ Confirmed the product risk classification result at the registration stage (Article 13(5))
• □ Made clear that exemption from batch assessment does not equal release from quality obligations
• □ Included the testing and monitoring under Article 12(4)(3) and (4) in post-market management

Regulatory information verified as of October 29, 2026.

In the Central Asia market, the core capabilities of GRZAN concentrate on three points. First, distinguishing the different legal positions of individual markets within the Eurasian Economic Union — Kazakhstan and Kyrgyzstan are full member states, where a national pathway and a Union pathway both exist; Uzbekistan is an observer state with only a national pathway; Tajikistan and Turkmenistan lie outside the Union framework and must proceed entirely under national procedures. Second, local authorized representative services, which may act as the statutory representative of manufacturers in these countries and assume registration submissions, regulatory communication and post-market reporting obligations. Third, quality system and testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

Business inquiries: info@grzanglobal.com